Table 5.

Primary efficacy endpoints: Intent-to-treat population —CLIN/RA gel versus clindamycin gel alone

EFFICACY PARAMETER	CLIN/RA GEL n=1008	CLINDAMYCIN GEL n=1002	PVALUE*
Dichotomized EGSS† percent success	37.8	31.7	0.002
PERCENT CHANGE FROM BASELINE TO WEEK 12
Noninflammatory lesion count mean ± SD	49.8 ±37.1	41.3 ±38.6	<0.001
Inflammatory lesion count mean ± SD	60.9 ± 35.8	54.8 ± 38.0	<0.001
Total lesions mean ± SD	54.5 ±31.6	46.9 ±32.9	<0.001

^*P values are based on a two-sided 5% test of the Cochran-Mantel-Haenszel Row Mean Score Statistic, adjusting for investigational center.

^†EGSS success was defined as clear or almost clear, or a 2-grade improvement from baseline.